Date:6/1/2011

er materially from those included in forward-looking statements due to a variety of factors.  More information about these factors can be found in Repro-Med's latest Annual Report filed with Securities and Exchange Commission on Form 10-K.  The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Andrew I. Sealfon, President
RMS Medical Products
24 Carpenter Road, Chester, NY 10918
Telephone: (845) 469-2042
FAX:  (845) 469-5518

'/>"/>

SOURCE Repro-Med Systems, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. FDA Approves Injectable Gel to Treat Fecal Incontinence
2. FDA approves Incivek for hepatitis C
3. FDA Approves Sutent for Rare Type of Pancreatic Cancer
4. FDA Approves New HIV Treatment
5. FDA Approves Victrelis for Hepatitis C
6. FDA Approves New Treatment for Rare Type of Pancreatic Cancer
7. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
8. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
9. FDA Approves New Treatment for Type 2 Diabetes
10. FDA Approves Zytiga for Late-Stage Prostate Cancer
11. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®